© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Quantum-Si Fourth Quarter and Full Year 2023 Earnings Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Katherine Atkinson from Quantum-Si. Katherine, please go ahead.
Good afternoon, everyone. Thank you for joining us. Earlier today, Quantum-Si released financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is available on the company's website. Joining me today are Jeff Hawkins, President and Chief Executive Officer; and Jeff Keyes, Chief Financial Officer. Before we begin, I would like to remind you that management will be making certain forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements of our press release. For a more complete list and description of risk factors, please see the company's filings made with the Securities and Exchange Commission. This conference call contains time-sensitive information that is accurate only as of the live broadcast today, February 29, 2024. Except as required by law, the company disclaims any intention or obligation to update or revise any forward-looking statements. During this call, we will also be referring to certain financial measures that are not prepared in accordance with U.S. generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the press release filed earlier today. With that, I will turn the call over to Jeff Hawkins.
Good afternoon, everyone, and thank you for joining us today. In today's call, we will provide a business update to present our fourth quarter and full year 2023 financial results and provide an outlook for 2024. We will then open the line for questions. As a reminder, the goal of Quantum-Si is to bring next-generation protein sequencing to every lab, everywhere. Our proprietary technology delivers deeper unbiased proteomics insights that we believe will accelerate scientific research, enable the discovery of new biomarkers and ultimately power the development of new therapies and diagnostic tests that will positively impact human health. Now I would like to provide an update on our progress during the quarter and full year ended December 31, 2023, as well as provide an outlook on 2024. Our first corporate priority is to commercialize platinum and the 2M chip. During 2023, we executed a controlled launch of our Platinum system. The controlled launch allowed us the opportunity to build our core commercial capabilities and processes and ultimately define the blueprint for how to scale these efforts in a financially sound way as we enter the full commercial launch phase. Also, during the controlled launch, we were able to engage deeply with key opinion leaders and early adopters of our technology to better understand their applications of interest, defined the focus of our technology development efforts going forward and deliver on the recent launch of our version 2 kit that I will talk about in a few moments. Based on the learnings from the controlled launch, during the fourth quarter of 2023 and into the start of 2024, we have been expanding our commercial infrastructure and resources in preparation for our full commercial launch. At present, we are finalizing our commercial readiness and expect our direct sales force and our current distributor network to be fully trained and ready to execute on our full commercial launch by the end of March. As we initiate our full commercial launch, I want to be clear about what this means for our customers and investors going forward. First, this means that we will no longer hold back the rate of instrument installations. All customers that are within our launch territories or are in areas where we can properly service and support them with our existing commercial infrastructure will be moved forward. Second, we will continue to closely monitor our commercial performance and customer success rates and leverage that data to execute on a steady scale-up of our commercial infrastructure, both direct and distribution throughout 2024. Finally, now that we are moving into our full commercial launch phase and have much better visibility to our R&D pipeline, we are pleased to be able to provide full year financial guidance, which we will talk about in a few minutes. Our commercial strategy involves a mix of direct sales and service and distribution partners. In the U.S. market, we currently operate with a direct sales and service model. In EMEA, our initial focus will be the European market where we will utilize a mix of direct and distribution approaches. Beyond the U.S. and EMEA markets, we recently announced the addition of a distribution partner in Japan, which we expect will serve as our strategic entry point into the broader APAC market in the quarters ahead. Our strategy is clear we will expand our commercial efforts in a fiscally responsible way, while ensuring all our customers receive the highest level of service and support. Our goal is not simply to place instruments it is to secure customers who will utilize our technology to advance their research for years to come. In preparation for full commercial launch, we have been diligently working to expand our direct commercial team across sales, marketing, service and support. Our direct commercial team now encompasses approximately 20 individuals based in the United States and Western Europe. On the distribution front, we have previously announced that we have secured 3 distribution partnerships covering Eastern Europe, Southern Europe and Japan. All 3 of these distribution partners have extensive experience bringing innovative new technologies to the market, and we look forward to partnering with them to ensure their success. In the last quarter, our sales funnel has continued to grow, and we expect that rate to accelerate in the near term based on our planned outbound marketing and direct selling efforts associated with our full commercial launch. Our funnel is well established to support the full commercial launch in both the United States and Europe. In addition, we continue to receive inquiries from other locations throughout the world, but we will not execute on those opportunities until we are confident that we have a sustainable infrastructure in place to service those customers to the highest standards we expect of ourselves. Lastly, One key takeaway from our controlled launch phase was how much value our platinum instrument can deliver to customers and they're surprised at how affordable the instrument is. To this end, effective January 1, 2024, we increased our list price for Platinum to $85,000. We believe this modest increase helps partially capture the exceptional value that Platinum provides relative to other tools in the market while continuing to be attractively priced. Our second priority is to lead with innovation. Quantum-Si is dedicated to meeting customer needs and enhancing their user experience. As we announced a few weeks ago, we launched our version 2 sequencing kit. This sequencing kit has substantial improvements over our prior version, including the introduction of a new amino acid recognizer, high reproducibility across runs and an approximately threefold reduction in cost for amino acid. The ability to deliver a high-performing new sequencing kit was a result of the R&D realignment that we completed in the third quarter of last year. As we reported previously, the initial signs coming out of the restructuring were promising. But now based on the team's performance over the last few months, I am pleased to conclude that the process was a success, and we are hitting on all cylinders. This version 2 sequencing kit is not the end, it is just the beginning. We expect to deliver a steady cadence of meaningful improvements to our technology going forward. In fact, we are already working on a version 3 sequencing kit, which we expect to deliver by the end of the third quarter. Though I can't share any specifics about the version 3 sequencing kit yet, I will say that our approach to releasing any new version of our sequencing kits is to ensure it will provide a meaningful improvement over the prior version further enabling our customers to expand their research efforts using next-generation protein sequencing. While the announcement of the launch of the Version 2 sequencing kit and the anticipated launch of a version 3 kit in the third quarter of this year is exciting news, it is not the end of our innovation road map. We are also making solid progress across library prep and instrument development programs that we believe will solidify our position as the technology leader in next-generation booking sequencing and will fuel the growth of the company for years to come. Finally, we are pleased to share that at the upcoming U.S. Human Proteome Organization Conference running from March 9th through the 13th, there will be a Quantum-Si customer giving an oral presentation regarding their use of platinum for PTM detection and a second customer presenting a poster describing their use of Platinum to develop alternative library prep applications for next-generation protein sequencing. We are excited to see customers beginning to present their work at industry conferences like [ Hoopa ] and expect to see more of this throughout 2024. Our third priority is to preserve financial strength. As we state on each of our calls, we remain committed to continuously improving our fiscal discipline. With Jeff Keyes, our Chief Financial Officer; and others joining the organization in the last year, we have significantly ramped up the discipline around our financial resources and planning efforts. This increased rigor, along with the clarity we have around our full commercial launch and the visibility we have to our R&D pipeline, allow us to be confident that we can provide more color to the investing community with our 2024 financial guidance. 2024 will be a transformational year for us as we embark on our full commercialization efforts. From our vantage point, we expect to generate revenue in the range of $3.7 million to $4.2 million, we expect growth on a quarter-over-quarter basis during 2024. Our 2024 revenue will include a mix of both platinum units and consumables, with the majority of revenue being derived from the United States along with contributions from the EMEA region. Jeff will provide further color on our 2024 guidance in a few moments. With our full commercial launch just a few weeks away, it has never been more important for us to utilize our financial resources in the most effective way, and we remain committed to that. With the actions that we took in the past and the discipline that we put in place over the last year, we are confident we will be able to achieve superior R&D results and speed to market and fully fund our commercialization efforts for 2024 and both with minimal changes in our operating expenses. I'll now turn the call over to Jeff Keyes to review our financial results. Jeff?
Thank you, Jeff. Now let's discuss the details of our fourth quarter and full year 2023 financial results. Revenue in the fourth quarter of 2023 was $400,000 which consisted of revenue from our Platinum instrument and associated consumable kits. Gross profit was $178,000 and gross margin was 45%. For the full year, revenue was $1.1 million, gross profit was $488,000 and gross margin was 45%. As I have stated before, our gross margin percentage will be somewhat variable for the near future as we work through our initial stages of commercialization and also will be impacted by the timing and mix of instruments versus consumable sales. Our margin will also be impacted in the near term by acquisition costs and any accounting adjustments to underlying inventory that dates back to the pre-commercial stage of Quantum-Si. GAAP total operating expenses in the fourth quarter of 2023 was $28.1 million compared to $38.8 million in the fourth quarter of 2022. Included within operating expenses are stock-based compensation, restructuring charges and goodwill impairment in the fourth quarter of 2022. Removing these items, we arrived at an adjusted operating expenses which were $26.3 million for the fourth quarter of 2023 compared to $25.3 million of the fourth quarter of 2022. For the full year of 2023, operating expenses were $111.7 million compared to $123.8 million for the full year of 2022 and adjusted operating expenses for the full year of 2023 were $98.9 million compared to $103.2 million for the full year 2022. The takeaway from our year-over-year reduction of adjusted operating expenses is that as a company, we have spent significant effort over the last year rightsizing our spend while also accelerating innovative product releases as demonstrated by our version 2 kit and funding a large part of our scaling our commercial operations. Net loss for the fourth quarter of 2023 was $22 million compared to $33.1 million in the fourth quarter of 2022 and adjusted EBITDA for the fourth quarter of 2023 was negative $25.1 million compared to negative $24.5 million in the fourth quarter of 2022. For the full year of 2023, net loss was $96 million compared to $132.4 million in 2022, and adjusted EBITDA for 2023 was negative $94.3 million compared to negative $100.6 million for 2022. As of December 31, 2023, we had $257.7 million in cash and cash equivalents and investments in marketable securities. Our full commercial launch plan includes a main focus of a direct sales channel approach in the United States market and a combination of direct and distributor approach in EMEA. Based on these approaches, we are guiding 2024 revenue to a range between $3.7 million and $4.2 million, adjusted operating expenses to be less than $103 million and net cash usage less than $100 million. In comparison, in 2023, we recorded $98.9 million in adjusted operating expenses and utilized $93.6 million in cash and investments. Our guidance for 2024 includes accelerated R&D innovation and fully funding our commercialization ramp-up with a minor increase to adjusted operating expenses and cash. As I stated earlier and on prior calls, we expect our gross margin percentage to be variable in the near term as we work through our initial stages of commercialization and the impact of acquisition costs and prior accounting adjustments to underlying inventory that dates back to the pre-commercial stage of Quantum-Si. Based on this, we're not providing specific gross margin guidance. Finally, we still expect that our existing cash, cash equivalents and investments in marketable securities will provide runway into 2026. Now I will turn the call over to the operator to open the line for questions.
[Operator Instructions]. Now first question coming from the line of Kyle Mikson with Canaccord.
This is Alex Vukasin on for Kyle Mikson. Just I think what we should start is a discussion of the guidance. Could you discuss particularly what the cadence of placements might be sequentially across the year? And more specifically, could there be a step down in 1Q from 4Q?
Yes. Thanks for the question. So we gave the guidance out on an annual basis. I think when you think about the quarterly cadence, I would expect, since we're just moving now into the full commercial launch as we get here towards the end of March, we'd expect there to be sort of a consistent rate of revenue here in the first quarter with some step up into Q2 and then more acceleration as you look into the back half of the year. So I don't anticipate a step down from Q4. I expect it to move maybe more laterally and then as I said, sort of accelerate in the back half of the year.
And so you also announced a lot of [ product ] improvements in early February, you announced version 3 kits here. And you also discussed [indiscernible] saw progress in regards to [ library ] prep. Just curious, could an instrument -- could carbon or an instrument [ proposition ] like carbon be offered in the near to medium term on these [ Sample Prep ].
Yes. I think when we think about library prep, I think you -- and you think about carbon too, right? So carbon, if you remember, was really for doing some of the front-end workflow automation. And our feedback from customers that we had accumulated last year that led to the decision to put carbon on hold was really there wasn't sort of the need for carbon based on the volumes of tests, our customers are processing and sort of the capabilities of the scientists and laboratory staff that are in those accounts. We continue to look at options, though, for automation as our customers scale up in volume. Really, the question will be, do we do that vis-a-vis a device like carbon or I think as we've communicated before, we're leaning more towards -- we would provide some form of liquid handling solution that could be from one that's available sort of in the existing market in terms of automating library prep and even other aspects of Sample Prep.
And one more question. In regards to potential adoption of protein sequencing. Obviously, it's still very much early days to the technology. You discussed some new posters coming out and it will be presented at a conference. Just curious kind of how you're seeing adoption levels right now and interest in protein sequencing, how that's kind of evolved since you've been out working on how that [indiscernible].
Sure. I think we talked about in prior calls, and I'd sort of reiterate a similar sentiment today. The interest in using next-generation protein sequencing has always been ahead of our expectations. We talked about the funnel during 2023 was running ahead of our expectations. I think as we entered 2024, we continue with the same sentiment. There's always been that interest there to utilize a technology like ours to be able to do types of analysis that are either very difficult to do today or aren't really accessible today for customers. So we see that interest. I think really now it's about with the version 2 kit with the increase in sort of commercial resources, getting all that trained, really now going out and executing on that full commercial launch and really converting that interest into customers who are adopting and using. I think the data that's coming out at [ Hopa ] is an example of customers who have access to this technology, they're going to start showing the applications and the types of things they can do. And as we accelerate the placement of our device with the full commercial launch. I'd expect that more and more people will talk about applications with the technology.
And our next question coming from the line Swayampakula Ramakanth from H.C. Wainwright.
This is RK from H.C. Wainwright. So between the webinar that happened a couple of days ago and the posters that are upcoming -- the poster and publication that's coming up in the conferences during a quarter, I guess, what's the takeaway from all this in the sense, if I am somebody who is looking for a platinum for buying platinum by looking at all these data presentations, would I get a good feel for what's the capabilities of the mission? Or is that just a small sample of set of things that the -- not from the utility of the machine.
Yes, it's a good question, RK. I would describe it as still a small sampling of what the technology and the platinum instrument are capable of. As you can imagine, with the broad capabilities of sequencing at the amino acid level, and still at the early phases of our commercialization efforts. These customers represent interesting applications. They represent applications that were of importance and priority for those customers, but they could be different for other users. So I expect that as more data comes out at future conferences and even at future webinars, you'll continue to see different things talked about. I don't think you're going to see a lot of repetition. I think you'll continue to see a breadth of applications that people are interested in.
Okay. And just staying on the same topic. Having -- being hardly in the market for a year, I'm able to get 3 different presentations out kind of speaks to the excitement to a certain extent of the utility of these machines, the same amount of enthusiasm palpitating among the funnel that you have? Or is this an indication of how large the funnel can go to once you start launching the product? I'm just trying to get a feel for like what would be the pull on the product once it becomes commercial?
Yes. I think about it in a couple of ways, RK. I think the first thing I would tell you is the interest in the technology and the excitement around a new technology like our technology, I think, is definitely palpable. It was in the controlled launch days. But as we've talked about on prior calls, that was really our decision, right, to roll out in a very controlled manner ensure we were able to be very responsive with any issues arose. It was -- we were really throttling the pace at which customers were able to access the technology. So that excitement has already sort of always been there. I think that excitement, I see it actually starting to accelerate with the V2 launch we put out some data and examples of performance increases you see at a protein level, at a peptide level [indiscernible] out data around the reproducibility enhancements in the product. And I think when you start providing information like that, again, serves to just show the innovation sort of trajectory we're on. So people are both excited about what we were talking about, but I think equally excited about the trajectory of innovation. I think as customers hear about a version 3 kit, it's only going to help with that. So I think we're -- while we're at the early stages because we're just moving to full commercial launch now, I would expect that excitement to be there and be sustained and grow, and that will show up ultimately in the funnel. And then it's our job to convert that sort of funnel and interest and excitement into placements and revenue as we move forward throughout the year.
Okay. And then my last question is in terms of, as you said, version 3 should be significantly different from Version 2 based on what you're suggesting. I know you don't want to kind of unveil what's going -- what we're going to see in version 3. But in terms of -- again, I'm just going back to the utility question again. So does when you start moving from version 1 to 2 to 3, what's the aim there? Is it to increase the spectrum of utility? Or is it more in terms of how well and how clean of a sequencing -- sequence can you get? What's the drive when you go from one version to the other.
Yes. When we move from one version to another, I think it's generally about an overall lift in performance, right, providing in this case, with the version 2 kit, we added an additional recognizer so you get more coverage manifests itself in terms of the number of visible amino acids. It manifests itself as being able to see more peptides from a given protein. But we also increased the overall output of the device. And that increased output gives customers then the flexibility to apply that in different ways. On one hand, with greater sequencing output per run, some customers might choose RK to apply that to look at a more complex sample, perhaps a more complex mixture of proteins. Other customers may want to apply that to really deeply interrogate samples and look at protein variants or PTMs in the future. So I think in general, the thinking is just continuing to raise the coverage, raise the output and the performance to really just give people a robust set of capabilities that they can then apply to their research in the way that they see fit. So it's really just about opening up applications capabilities compatibility with different samples they might want to work with. And then we really see where they go with their research and how they apply it, and we'll take those learnings like we did in the creation of V2 and they're fueling what we're doing in V3, and I'm sure they'll fuel what we do in a future version after that. I think V3 is very exciting. we're well underway, but I don't think that's the end either. And we'll learn in the market and we'll apply those learnings as we go forward.
And I'm showing no further questions in the queue at this time. I will now turn the call back over to Mr. Jeff Hawkins for any closing remarks.
Thank you. We continue to make significant progress at Quantum-Si on all fronts, and I want to thank the entire QSI team for their contributions during 2023. We're excited about our full year of commercial execution and R&D innovation, and we look forward to providing additional updates on our next call.
Ladies and gentlemen, that does conclude our conference for today. Thank you all for your participation. You may now disconnect.